IL6R and myocardial infarction: In the ASSAIL-MI trial, we have shown that IL-6R inhibition by tocilizumab improved myocardial salvage index (MSI) and microvascular obstruction (MVO) at 3–7 days following MI, of which the latter could be a sign of adverse myocardial remodeling [87].